Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health www.cancer.gov
CCR - For Our Staff| Home |

Our Science – Burke Website

Terrence R. Burke Jr., Ph.D.

Selected Publications
1)  Zhao X, Burke T. Neamati N, eds.
Application of protein modification to studying the structure and function of HIV-1 integrase and its inhibitors. In: HIV-1 integrase: Mechanism and inhibitor design. Volume .
Hoboken, NJ: Wiley & Sons; 2008. In Press. [Book Chapter]
2)  Zhao XZ, Semenova EA, Vu BC, Maddali K, Marchand C, Hughes SH, Pommier Y, Burke TR.
2,3-dihydro-6,7-dihydroxy-1H-isoindol-1-one-based HIV-1 integrase inhibitors.
J. Med. Chem. 51: 251-9, 2008. [Journal]
3)  Hofer T, Thomas JD, Burke TR, Rader C.
An engineered selenocysteine defines a unique class of antibody derivatives.
Proc. Natl. Acad. Sci. U.S.A. 105: 12451-6, 2008. [Journal]
4)  Thomas JD, Hofer T, Rader C, Burke TR.
Application of a trifunctional reactive linker for the construction of antibody-drug hybrid conjugates.
Bioorg. Med. Chem. Lett. 2008. [Journal]
5)  Giubellino A, Burke TR, Bottaro DP.
Grb2 signaling in cell motility and cancer.
Expert Opin. Ther. Targets. 12: 1021-33, 2008. [Journal]
6)  Liu F, Stephen AG, Fisher RJ, Burke TR.
Protected aminooxyprolines for expedited library synthesis: application to Tsg101-directed proline-oxime containing peptides.
Bioorg. Med. Chem. Lett. 18: 1096-1101, 2008. [Journal]
7)  Liu F, Stephen AG, Waheed AA, Aman MJ, Freed EO, Fisher RJ, Burke TR.
SAR by Oxime-Containing Peptide Libraries: Application to Tsg101 Ligand Optimization.
Chembiochem. 9: 2000-2004, 2008. [Journal]
8)  Giubellino A, Shi Z, Jenkins LM, Worthy KM, Bindu LK, Athauda G, Peruzzi B, Fisher RJ, Appella E, Burke TR, Bottaro DP.
Selectivity and Mechanism of Action of a Growth Factor Receptor-Bound Protein 2 Src Homology 2 Domain Binding Antagonist.
J. Med. Chem. 51: 7459-7468, 2008. [Journal]
9)  Ogura K, Shiga T, Yokochi M, Yuzawa S, Burke TR, Inagaki F.
Solution structure of the Grb2 SH2 domain complexed with a high-affinity inhibitor.
J. Biomol. NMR. 42: 197-207, 2008. [Journal]
10)  Liu F, Thomas J, Burke, Jr. TR.
Synthesis of a homologous series of side-chain-extended orthogonally protected aminooxy-containing amino acids.
Synthesis. 15: 2432-2438, 2008. [Journal]
11)  Kim HJ, Kim JY, Meng Z, Wang LH, Liu F, Conrads TP, Burke TR, Veenstra TD, Farrar WL.
15-deoxy-Delta12,14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-alpha via covalent modification of DNA-binding domain.
Cancer Res. 67: 2595-602, 2007. [Journal]
12)  Nolan KA, Zhao H, Faulder PF, Frenkel AD, Timson DJ, Siegel D, Ross D, Burke TR, Stratford IJ, Bryce RA.
Coumarin-based inhibitors of human NAD(P)H: quinone oxidoreductase-1. identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity.
J. Med. Chem. 50: 6316-25, 2007. [Journal]
13)  Kang SU, Choi WJ, Oishi S, Lee K, Karki RG, Worthy KM, Bindu LK, Nicklaus MC, Fisher RJ, Burke TR.
Examination of acylated 4-aminopiperidine-4-carboxylic acid residues in the phosphotyrosyl+1 position of Grb2 SH2 domain-binding tripeptides.
J. Med. Chem. 50: 1978-82, 2007. [Journal]
14)  Giubellino A, Gao Y, Lee S, Lee MJ, Vasselli JR, Medepalli S, Trepel JB, Burke TR, Bottaro DP.
Inhibition of tumor metastasis by a growth factor receptor bound protein 2 Src homology 2 domain-binding antagonist.
Cancer Res. 67: 6012-6, 2007. [Journal]
15)  Choi WJ, Kang S, Burke T.
Preparation of orthogonally-protected 3-methoxy-4-phosphonomethyl-L-phenylalanine, a new reagent for the synthesis of phosphotyrosyl mimetic-containing peptides.
Lett. Org. Chem. 4: 433-439, 2007. [Journal]
16)  Johnson AA, Marchand C, Patil SS, Costi R, Di Santo R, Burke TR, Pommier Y.
Probing HIV-1 integrase inhibitor binding sites with position-specific integrase-DNA cross-linking assays.
Mol. Pharmacol. 71: 893-901, 2007. [Journal]
17)  Liu F, Worthy KM, Bindu LK, Fisher RJ, Burke TR.
Structural examination of ring-closing metathesis-derived 15-member macrocycles as Grb2 SH2 domain-binding tetrapeptide mimetics.
J. Org. Chem. 72: 9635-42, 2007. [Journal]
18)  Liu F, Worthy KM, Bindu L, Giubellino A, Bottaro DP, Fisher RJ, Burke TR.
Utilization of achiral alkenyl amines for the preparation of high affinity Grb2 SH2 domain-binding macrocycles by ring-closing metathesis.
Org. Biomol. Chem. 5: 367-72, 2007. [Journal]
19)  Choi WJ, Shi ZD, Worthy KM, Bindu L, Karki RG, Nicklaus MC, Fisher RJ, Burke TR.
Application of azide-alkyne cycloaddition 'click chemistry' for the synthesis of Grb2 SH2 domain-binding macrocycles.
Bioorg. Med. Chem. Lett. 16: 5265-9, 2006. [Journal]
20)  Zhao XZ, Semenova EA, Liao C, Nicklaus M, Pommier Y, Burke TR.
Biotinylated biphenyl ketone-containing 2,4-dioxobutanoic acids designed as HIV-1 integrase photoaffinity ligands.
Bioorg. Med. Chem. 14: 7816-25, 2006. [Journal]
21)  Burke TR.
Design and synthesis of phosphonodifluoromethyl phenylalanine (F2Pmp): a useful phosphotyrosyl mimetic.
Current topics in medicinal chemistry. 6: 1465-71, 2006. [Journal]
22)  Burke Jr TR.
Development of Grb2 SH2 domain signaling antagonists: A potential new class of antiproliferative agents.
Int J Pept Res Therap. 12: 33-48, 2006. [Journal]
23)  Al-Mawsawi LQ, Fikkert V, Dayam R, Witvrouw M, Burke TR, Borchers CH, Neamati N.
Discovery of a small-molecule HIV-1 integrase inhibitor-binding site.
Proc. Nat. Acad. Sci. USA. 103: 10080-10085, 2006. Full Text Article. [Journal]
24)  Johnson AA, Sayer JM, Yagi H, Patil SS, Debart F, Maier MA, Corey DR, Vasseur JJ, Burke TR, Marquez VE, Jerina DM, Pommier Y.
Effect of DNA modifications on DNA processing by HIV-1 integrase and inhibitor binding: role of DNA backbone flexibility and an open catalytic site.
J. Biol. Chem. 281: 32428-38, 2006. [Journal]
25)  Baba M, Hong SB, Sharma N, Warren MB, Nickerson ML, Iwamatsu A, Esposito D, Gillette WK, Hopkins RF, Hartley JL, Furihata M, Oishi S, Zhen W, Burke TR, Linehan WM, Schmidt LS, Zbar B.
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling.
Proc. Natl. Acad. Sci. U.S.A. 103: 15552-7, 2006. [Journal]
26)  Liu F, Stephen AG, Adamson CS, Gousset K, Aman MJ, Freed EO, Fisher RJ, Burke TR.
Hydrazone- and Hydrazide-Containing N-Substituted Glycines as Peptoid Surrogates for Expedited Library Synthesis: Application to the Preparation of Tsg101-Directed HIV-1 Budding Antagonists.
Org Lett. 8: 5165-5168, 2006. [Journal]
27)  Johnson AA, Santos W, Pais GC, Marchand C, Amin R, Burke TR, Verdine G, Pommier Y.
Integration requires a specific interaction of the donor DNA terminal 5'-cytosine with glutamine 148 of the HIV-1 integrase flexible loop.
J Biol Chem. 281: 461-7, 2006. [Journal]
28)  Dharmawardana PG, Peruzzi B, Giubellino A, Burke TR, Bottaro DP.
Molecular targeting of growth factor receptor-bound 2 (Grb2) as an anti-cancer strategy.
Anticancer Drugs. 17: 13-20, 2006. [Journal]
29)  Li M, Mizuuchi M, Burke TR, Craigie R.
Retroviral DNA integration: reaction pathway and critical intermediates.
EMBO J. 25: 1295-304, 2006. [Journal]
30)  Jiang S, Li P, Peach ML, Bindu L, Worthy KW, Fisher RJ, Burke TR, Nicklaus M, Roller PP.
Structure-based design of potent Grb2-SH2 domain antagonists not relying on phosphotyrosine mimics.
Biochem. Biophys. Res. Commun. 349: 497-503, 2006. [Journal]
31)  Oishi S, Shi ZD, Karki RG, Worthy KM, Bindu L, Chertov O, Esposito D, Frank P, Gillette WK, Maderia M, Barchi Jr JJ, Nicklaus MC, Hartley J, Fisher RJ, Burke Jr TR. Shimohigashi Y, eds.
Application of beta-branched allylglycine equivalents to macrocyclic Grb2 SH2 domain-binding inhibitors. In: Peptide Science 2004. Volume .
Osaka: The Japanese Peptide Society; 2005. p. 123-126 [Book Chapter]
32)  Oishi S, Kang UK, Karki RG, Worthy KM, Bindu L, Chertov O, Esposito D, Frank P, Gillette WK, Nicklaus MC, Hartley J, Fisher RJ, Burke Jr TR. Shimohigashi Y, eds.
Synthesis and application of novel phosphotyrosyl mimetics to Grb2 SH2 domain-binding inhibitors. In: Peptide Science 2004. Volume .
Osaka: The Japanese Peptide Society; 2005. p. 397-400 [Book Chapter]
33)  Kang S, Choi W, Shi Z, Karki R, Worthy K, Bindu L, Nicklaus M, Waugh D, Fisher R, Burke Jr T. Blondelle S, eds.
Application of phenylphosphate mimetics to the design and synthesis of olefin metathesis-derived Grb2 SH2 domain-binding macrocycles. In: Understanding Biology Using Peptides. Volume .
La Costa, CA: American Peptide Society; 2005. p. 180-181 [Book Chapter]
34)  Liu F, Oishi S, Shi Z, Karki R, Worthy K, Bindu L, Maderia M, Nicklaus M, Barchi Jr J, Fisher R, Burke Jr T. Blondelle S, eds.
High affinity Grb2 SH2 domain-binding macrocycles derived from ring-closing metathesis of alkenylglycine residues with beta-vinyl phosphotyrosyl mimetics. In: Understanding Biology Using Peptides. Volume .
La Costa, CA: American Peptide Society; 2005. p. 559-560 [Book Chapter]
35)  Shi Z, Dharmawardana P, Giubellino A, Appella E, Worthy K, Bindu L, Fisher R, Burke Jr T. Blondelle S, eds.
Synthesis and use of C-terminally biotinylated peptidomimetics with high Grb2 SH2 domain-binding affinity. In: Understanding Biology Using Peptides. Volume .
La Costa, CA: American Peptide Society; 2005. p. 208-209 [Book Chapter]
36)  Phan J, Shi ZD, Burke TR, Waugh DS.
Crystal Structures of a High-affinity Macrocyclic Peptide Mimetic in Complex with the Grb2 SH2 Domain.
J Mol Biol. 353: 104-15, 2005. [Journal]
37)  Kang SU, Worthy KM, Bindu LK, Zhang M, Yang D, Fisher RJ, Burke TR.
Design and synthesis of 4-(alpha-hydroxymalonyl)phenylalanine as a new phosphotyrosyl mimetic and its use in growth factor receptor bound 2 src-homology 2 (Grb2 SH2) domain-binding peptides.
J Med Chem. 48: 5369-72, 2005. [Journal]
38)  Oishi S, Karki RG, Kang SU, Wang X, Worthy KM, Bindu LK, Nicklaus MC, Fisher RJ, Burke TR.
Design and synthesis of conformationally constrained Grb2 SH2 domain binding peptides employing alpha-methylphenylalanyl based phosphotyrosyl mimetics.
J Med Chem. 48: 764-72, 2005. [Journal]
39)  Plasencia C, Dayam R, Wang Q, Pinski J, Burke TR, Quinn DI, Neamati N.
Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines.
Mol Cancer Ther. 4: 1105-13, 2005. [Journal]
40)  Oishi S, Karki RG, Shi ZD, Worthy KM, Bindu L, Chertov O, Esposito D, Frank P, Gillette WK, Maderia M, Hartley J, Nicklaus MC, Barchi JJ, Fisher RJ, Burke TR.
Evaluation of macrocyclic Grb2 SH2 domain-binding peptide mimetics prepared by ring-closing metathesis of C-terminal allylglycines with an N-terminal beta-vinyl-substituted phosphotyrosyl mimetic.
Bioorg Med Chem. 13: 2431-8, 2005. [Journal]
41)  Kang SU, Shi ZD, Worthy KM, Bindu LK, Dharmawardana PG, Choyke SJ, Bottaro DP, Fisher RJ, Burke TR.
Examination of phosphoryl-mimicking functionalities within a macrocyclic Grb2 SH2 domain-binding platform.
J Med Chem. 48: 3945-8, 2005. [Journal]
42)  Yao ZJ, Lee K, Burke TR.
Incorporation of phosphotyrosyl mimetic 4-(phosphonodifluoromethyl)phenylalanine (F2Pmp) into signal transduction-directed peptides.
Methods Mol Biol. 298: 91-103, 2005. [Journal]
43)  Oishi S, Shi Z, Worthy KM, Bindu LK, Fisher RJ, Burke TR.
Ring-Closing Metathesis of C-Terminal Allylglycine Residues with an N-Terminal beta-Vinyl-Substituted Phosphotyrosyl Mimetic as an Approach to Novel Grb2 SH2 Domain-Binding Macrocycles.
Chembiochem. 6: 668-674, 2005. [Journal]
44)  Shi ZD, Liu H, Zhang M, Worthy KM, Bindu L, Yang D, Fisher RJ, Burke TR.
Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity.
Bioorg Med Chem. 13: 4200-8, 2005. [Journal]
45)  Lee K, Boovanahalli SK, Nam KY, Kang SU, Lee M, Phan J, Wu L, Waugh DS, Zhang ZY, No KT, Lee JJ, Burke TR.
Synthesis of tripeptides as potent Yersinia protein tyrosine phosphatase inhibitors.
Bioorg Med Chem Lett. 15: 4037-42, 2005. [Journal]
46)  Shi ZD, Karki RG, Worthy KM, Bindu LK, Nicklaus MC, Fisher RJ, Burke TR.
Utilization of a common pathway for the synthesis of high affinity macrocyclic Grb2 SH2 domain-binding peptide mimetics that differ in the configuration at one ring junction.
Chem. Biodivers. 2: 447-56, 2005. [Journal]
47)  Shi ZD, Karki RG, Oishi S, Worthy KM, Bindu LK, Dharmawardana PG, Nicklaus MC, Bottaro DP, Fisher RJ, Burke TR.
Utilization of a nitrobenzoxadiazole (NBD) fluorophore in the design of a Grb2 SH2 domain-binding peptide mimetic.
Bioorg Med Chem Lett. 15: 1385-8, 2005. [Journal]
48)  Kang SU, Burke Jr TR.
A one-step synthesis of N-Fmoc-4-O[O',"-di-tert-butyl-2-(2-fluoromalonyl)]-L-tyrosine from commercially-available starting material.
Tetrahedron Lett. 45: 8611-86-13, 2004. [Journal]
49)  Svarovskaia ES, Barr R, Zhang X, Pais GC, Marchand C, Pommier Y, Burke TR, Pathak VK.
Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctions.
J Virol. 78: 3210-22, 2004. [Journal]
50)  Zhang X, Marchand C, Pommier Y, Burke TR.
Design and synthesis of photoactivatable aryl diketo acid-containing HIV-1 integrase inhibitors as potential affinity probes.
Bioorg Med Chem Lett. 14: 1205-7, 2004. [Journal]
51)  Kang SU, Gao Y, Wu L, Zhang ZY, Burke Jr TR.
Enantioselective synthesis of (S)-3-carboxy-4 ((carboxy)difluoromethyl)phenylalanine in protected form and incorporation into a PTP-1B-directed tripeptide.
Chem. Biodiversity. 1: 626-633, 2004. [Journal]
52)  Kang SU, Gao Y, Wu L, Zhang ZY, Burke TR.
Enantioselective synthesis of (S)-3-carboxy-4-((carboxy)difluoromethyl)phenylalanine in protected form and its incorporation into a PTP-1B-directed tripeptide.
Chem. Biodivers. 1: 626-33, 2004. [Journal]
53)  Wang X, Burke Jr TR.
Enantioselective synthesis of ureapeptoid-containing macrocycles.
Synlett. 3: 469-472, 2004. [Journal]
54)  Shkriabai N, Patil SS, Hess S, Budihas SR, Craigie R, Burke TR, Le Grice SF, Kvaratskhelia M.
Identification of an inhibitor-binding site to HIV-1 integrase with affinity acetylation and mass spectrometry.
Proc Natl Acad Sci U S A. 101: 6894-9, 2004. [Journal]
55)  Soriano JV, Liu N, Gao Y, Yao ZJ, Ishibashi T, Underhill C, Burke TR, Bottaro DP.
Inhibition of angiogenesis by growth factor receptor bound protein 2-Src homology 2 domain bound antagonists.
Mol Cancer Ther. 3: 1289-99, 2004. [Journal]
56)  Shi ZD, Wei CQ, Lee K, Liu H, Zhang M, Araki T, Roberts LR, Worthy KM, Fisher RJ, Neel BG, Kelley JA, Yang D, Burke TR.
Macrocyclization in the design of non-phosphorus-containing Grb2 SH2 domain-binding ligands.
J Med Chem. 47: 2166-9, 2004. [Journal]
57)  Shi ZD, Wei CQ, Lee K, Liu H, Zhang M, Bottaro DP, Linehan WM, Yang D, Burke Jr TR.
Macrocyclization in the design of tetra-peptide mimetics that display potent inhibition of Grb2 SH2 domain binding in whole cell systems.
Peptide Revolution: Genomics, Proteomics & Therapeutics. Proc 18th Am Pep Sym: 515-517, 2004. [Journal]
58)  Karki RG, Tang Y, Burke TR, Nicklaus MC.
Model of full-length HIV-1 integrase complexed with viral DNA as template for anti-HIV drug design.
J. Comput. Aided Mol. Des. 18: 739-60, 2004. [Journal]
59)  Valizadeh M, Schenk G, Nash K, Oddie GW, Guddat LW, Hume DA, de Jersey J, Burke TR, Hamilton S.
Phosphotyrosyl peptides and analogues as substrates and inhibitors of purple acid phosphatases.
Arch Biochem Biophys. 424: 154-62, 2004. [Journal]
60)  Shi ZD, Lee K, Wei CQ, Roberts LR, Worthy KM, Fisher RJ, Burke TR.
Synthesis of a 5-methylindolyl-containing macrocycle that displays ultrapotent Grb2 SH2 domain-binding affinity.
J Med Chem. 47: 788-91, 2004. [Journal]
61)  Oishi S, Kang SU, Liu H, Zhang M, Yang D, Burke Jr TR.
Synthesis of alpha, alpha-disubstituted 4-phosphonophenylalanine analogues as conformationally-constrained phosphotyrosyl mimetics.
Tetrahedron. 60: 2971-2977, 2004. [Journal]
62)  Shi ZD, Liu H, Zhang M, Yang D, Burke Jr TR.
Synthesis of the first alpha-fluorophosphotyrosyl mimetic.
Synth Comm. 34: 2883-2889, 2004. [Journal]
63)  Lee K, Gao Y, Phan J, Wu L, Liang J, Zhang ZY, Waugh D, Burke Jr TR.
Tripeptide inhibitors of Yersinia protein-tyrosine phosphatase as potential leads for therapeutic development against plague.
Peptide Revolution: Genomics, Proteomics & Therapeutics. Proc 18th Am Pep Sym: 544-545, 2004. [Journal]
64)  Shi ZD, Lee K, Liu H, Zhang M, Roberts LR, Worthy KM, Fivash MJ, Fisher RJ, Yang D, Burke TR.
A novel macrocyclic tetrapeptide mimetic that exhibits low-picomolar Grb2 SH2 domain-binding affinity.
Biochem Biophys Res Commun. 310: 378-383, 2003. [Journal]
65)  Liu DG, Gao Y, Voigt JH, Lee K, Nicklaus MC, Wu L, Zhang ZY, Burke TR.
Acylsulfonamide-containing PTP1B inhibitors designed to mimic an enzyme-bound water of hydration.
Bioorg Med Chem Lett. 13: 3005-7, 2003. [Journal]
66)  Zhang X, Pais GC, Svarovskaia ES, Marchand C, Johnson AA, Karki RG, Nicklaus MC, Pathak VK, Pommier Y, Burke TR.
Azido-Containing aryl beta-Diketo acid HIV-1 integrase inhibitors.
Bioorg Med Chem Lett. 13: 1215-9, 2003. [Journal]
67)  Lee K, Burke TR.
CD45 Protein-Tyrosine Phosphatase Inhibitor Development.
Curr Top Med Chem. 3: 797-807, 2003. [Journal]
68)  Phan J, Lee K, Cherry S, Tropea JE, Burke TR, Waugh DS.
High-Resolution Structure of the Yersinia pestis Protein Tyrosine Phosphatase YopH in Complex with a Phosphotyrosyl Mimetic-Containing Hexapeptide.
Biochemistry. 42: 13113-21, 2003. [Journal]
69)  Wei CQ, Gao Y, Lee K, Guo R, Li B, Zhang M, Yang D, Burke TR.
Macrocyclization in the design of Grb2 SH2 domain-binding ligands exhibiting high potency in whole-cell systems.
J Med Chem. 46: 244-54, 2003. [Journal]
70)  Marchand C, Johnson AA, Karki RG, Pais GC, Zhang X, Cowansage K, Patel TA, Nicklaus MC, Burke TR, Pommier Y.
Metal-dependent inhibition of HIV-1 integrase by beta-diketo acids and resistance of the soluble double-mutant (F185K/C280S).
Mol Pharmacol. 64: 600-9, 2003. [Journal]
71)  Burke TR, Lee K.
Phosphotyrosyl mimetics in the development of signal transduction inhibitors.
Acc Chem Res. 36: 426-33, 2003. [Journal]
72)  Wang XZ, Yao ZJ, Liu HP, Zhang MC, Yang DJ, George C, Burke TR.
Synthesis of a Phosphotyrosyl Analogue Having X-1, X-2 and Phi Angles Constrained to Values Observed for an SH2 Domain-bound Phosphotyrosyl Residue.
Tetrahedron. 59: 6087-6093, 2003. [Journal]
73)  Lee K, Gao Y, Yao ZJ, Phan J, Wu L, Liang J, Waugh DS, Zhang ZY, Burke TR.
Tripeptide inhibitors of Yersinia protein-tyrosine phosphatase.
Bioorg Med Chem Lett. 13: 2577-81, 2003. [Journal]
74)  Lee K, Kang SU, Gao Y, Zhu-Jun Y, Phan J, Wu L, Liang J, Waugh DS, Zhang ZY, Burke Jr TR.
Tripeptide inhibitors of yersinia protein-tyrosine phosphatase as potential leads for therapeutic development against plague.
Peptide Revolution: Genomics, Proteomics & Therapeutics. Ed: M Chorev, TK Sawyer: 544-555, 2003. [Journal]
75)  Lee K, Zhang M, Liu H, Yang D, Burke TR.
Utilization of a beta-aminophosphotyrosyl mimetic in the design and synthesis of macrocyclic Grb2 SH2 domain-binding peptides.
J Med Chem. 46: 2621-30, 2003. [Journal]
76)  Svarovskaia ES, Barr R, Zhang X, Pais GCG, Marchand C, Pommier Y, Burke TR, Pathak VK.
Azide Group Containing 3-Aryl-1,3-Diketo Acid Derivatives Are Potent Inhibitors of HIV-1 Replication.
Antiviral Therapy. 7: 15-, 2002. [Journal]
77)  Lee K, Zhang M, Yang D, Burke TR.
Design and synthesis of a beta-amino phosphotyrosyl mimetic suitably protected for peptide synthesis.
Bioorg Med Chem Lett. 12: 3399-401, 2002. [Journal]
78)  Wei CQ, Li B, Guo R, Yang D, Burke TR.
Development of a phosphatase-stable phosphotyrosyl mimetic suitably protected for the synthesis of high-affinity Grb2 SH2 domain-binding ligands.
Bioorg Med Chem Lett. 12: 2781-4, 2002. [Journal]
79)  Melek M, Jones JM, O'Dea MH, Pais G, Burke TR, Pommier Y, Neamati N, Gellert M.
Effect of HIV integrase inhibitors on the RAG1/2 recombinase.
Proc Natl Acad Sci U S A. 99: 134-7, 2002. [Journal]
80)  Liu DG, Gao Y, Wang X, Kelley JA, Burke TR.
Enantioselective synthesis of N(alpha)-Fmoc protected (2S,3R)-3-phenylpipecolic acid. A constrained phenylalanine analogue suitably protected for solid-phase peptide synthesis.
J Org Chem. 67: 1448-52, 2002. [Journal]
81)  Pluymers W, Pais G, Van Maele B, Pannecouque C, Fikkert V, Burke TR, De Clercq E, Witvrouw M, Neamati N, Debyser Z.
Inhibition of human immunodeficiency virus type 1 integration by diketo derivatives.
Antimicrob Agents Chemother. 46: 3292-7, 2002. [Journal]
82)  Neamati N, Lin Z, Karki RG, Orr A, Cowansage K, Strumberg D, Pais GC, Voigt JH, Nicklaus MC, Winslow HE, Zhao H, Turpin JA, Yi J, Skalka AM, Burke TR, Pommier Y.
Metal-dependent inhibition of HIV-1 integrase.
J Med Chem. 45: 5661-70, 2002. [Journal]
83)  Pais GCG, Burke TR.
Novel Aryl Diketo-Containing Inhibitors of HIV-1 Integrase.
Drug Future. 27: 1101-1111, 2002. [Journal]
84)  Marchand C, Zhang X, Pais GC, Cowansage K, Neamati N, Burke TR, Pommier Y.
Structural determinants for HIV-1 integrase inhibition by beta-diketo acids.
J Biol Chem. 277: 12596-603, 2002. [Journal]
85)  Pais GC, Zhang X, Marchand C, Neamati N, Cowansage K, Svarovskaia ES, Pathak VK, Tang Y, Nicklaus M, Pommier Y, Burke TR.
Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors.
J Med Chem. 45: 3184-94, 2002. [Journal]
86)  Liu DG, Wang XZ, Gao Y, Li BH, Yang D, Burke TR.
Synthesis of N-Fmoc 3-(4-(di-tert-butyl)phosphonomethyl)phenyl)pipecolic acid as a Conformationally Constrained Phosphotyrosyl Mimetic Suitably Protected for Peptide Synthesis.
Tetrahedron. 58: 10423-10428, 2002. [Journal]
87)  Burke Jr TR, Liu DG, Voigt J, Wu L, Zhang ZY, Gao Y.
A focused library approach to PTP inhibitor discovery predicated on the x-ray structure of a PTP1B-bound lead compound.
Proc 17th Amer Pep Symp. Houghten RA and Lebl M (eds): 868-869, 2001. [Journal]
88)  Zhang X, Neamati N, Lee YK, Orr A, Brown RD, Whitaker N, Pommier Y, Burke TR.
Arylisothiocyanate-containing esters of caffeic acid designed as affinity ligands for HIV-1 integrase.
Bioorg Med Chem. 9: 1649-57, 2001. [Journal]
89)  Liu DG, Gao Y, Wei CQ, Voigt J, Wu J, Yang DJ, Burke Jr TR.
Local conformational constraint in the design of a Grb2 SH2 domain inhibitor.
Proc 17th Amer Pep Symp. Houghten RA and Lebl M (eds): 863-864, 2001. [Journal]
90)  Gao Y, Voigt J, Wu JX, Yang D, Burke TR.
Macrocyclization in the design of a conformationally constrained Grb2 SH2 domain inhibitor.
Bioorg Med Chem Lett. 11: 1889-92, 2001. [Journal]
91)  Burke TR, Yao ZJ, Gao Y, Wu JX, Zhu X, Luo JH, Guo R, Yang D.
N-terminal carboxyl and tetrazole-containing amides as adjuvants to Grb2 SH2 domain ligand binding.
Bioorg Med Chem. 9: 1439-45, 2001. [Journal]
92)  Gao Y, Wei CQ, Burke TR.
Olefin metathesis in the design and synthesis of a globally constrained Grb2 SH2 domain inhibitor.
Org Lett. 3: 1617-20, 2001. [Journal]
93)  Burke TR, Yao ZJ, Ye B, Miyoshi K, Otaka A, Wu L, Zhang ZY.
Phospho-Azatyrosine, a less effective protein-tyrosine phosphatase substrate than phosphotyrosine.
Bioorg Med Chem Lett. 11: 1265-8, 2001. [Journal]
94)  Burke TR, Yao ZJ, Liu DG, Voigt J, Gao Y.
Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors.
Biopolymers. 60: 32-44, 2001. [Journal]
95)  Atabey N, Gao Y, Yao ZJ, Breckenridge D, Soon L, Soriano JV, Burke TR, Bottaro DP.
Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions.
J Biol Chem. 276: 14308-14, 2001. [Journal]
96)  Vandegraaff N, Kumar R, Hocking H, Burke TR, Mills J, Rhodes D, Burrell CJ, Li P.
Specific inhibition of human immunodeficiency virus type 1 (HIV-1) integration in cell culture: putative inhibitors of HIV-1 integrase.
Antimicrob Agents Chemother. 45: 2510-6, 2001. [Journal]
97)  Gao Y, Voigt J, Zhao H, Pais GC, Zhang X, Wu L, Zhang ZY, Burke TR.
Utilization of a peptide lead for the discovery of a novel PTP1B-binding motif.
J Med Chem. 44: 2869-78, 2001. [Journal]
98)  Orban Z, Mitsiades N, Burke TR, Tsokos M, Chrousos GP.
Caffeic acid phenethyl ester induces leukocyte apoptosis, modulates nuclear factor-kappa B and suppresses acute inflammation.
Neuroimmunomodulation. 7: 99-105, 2000. [Journal]
99)  Yao ZJ, Barchi Jr JJ, Burke Jr TR.
Design and synthesis of a new tyrosine analogue having chi1 and chi2 angles constrained to values observed for an SH2-domain-bound phosphotyrosyl residue.
Peptides for the New Millennium. Fields GB, Tam JP, Barany G (eds), Kluwer Acad Pub: 576-578, 2000. [Journal]
100)  Gao Y, Wu L, Luo JH, Guo R, Yang D, Zhang ZY, Burke TR.
Examination of novel non-phosphorus-containing phosphotyrosyl mimetics against protein-tyrosine phosphatase-1B and demonstration of differential affinities toward Grb2 SH2 domains.
Bioorg Med Chem Lett. 10: 923-7, 2000. [Journal]
101)  Bandyopadhyay G, Sajan MP, Kanoh Y, Standaert ML, Burke TR, Quon MJ, Reed BC, Dikic I, Noel LE, Newgard CB, Farese R.
Glucose activates mitogen-activated protein kinase (extracellular signal-regulated kinase) through proline-rich tyrosine kinase-2 and the Glut1 glucose transporter.
J Biol Chem. 275: 40817-26, 2000. [Journal]
102)  Long YQ, Lung FDT, Voigt JH, Yao ZJ, Burke Jr TR, Yang D, Luo JH, Guo R, King CR, Roller PP.
High affinity nonphosphorylated cyclic peptide inhibitors of Grb2-SH2/growth factor receptor interactions.
Peptides for the New Millennium. Fields GB, Tam JP, Barany G (eds), Kluwer Acad Pub: 568-570, 2000. [Journal]
103)  Gao Y, Luo J, Yao ZJ, Guo R, Zou H, Kelley J, Voigt JH, Yang D, Burke TR.
Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic.
J Med Chem. 43: 911-20, 2000. [Journal]
104)  Liu DG, Yao ZJ, Gao Y, Burke TR.
Large Scale Preparation of Cell Permeable, Non-phosphate-containing GRB2 SH2 Domain Inhibitors.
Org Prep Proc Intl. 32: 197-201, 2000. [Journal]
105)  Gao Y, Yao ZJ, Voigt JH, Luo JH, Yang D, Burke Jr TR.
Novel phosphotyrosyl mimetics for the preparation of potent small molecule Grb2 SH2 domain inhibitors.
Peptides for the New Millennium. Fields GB, Tam JP, Barany G (eds), Kluwer Acad Pub: 566-567, 2000. [Journal]
106)  Burke Jr TR, Gao Y, Yao ZJ.
Phosphotyrosyl mimetics as signalling modulators and potential antitumor agents.
Biomedical Chemistry: Applying Chemical Principles to the Understanding and Treatment of Disease. Ed. Paul Torrence, John Wiley and Sons, NY, NY: 189-210, 2000. [Journal]
107)  Burke Jr TR, Gao Y, Yao ZJ, Voigt J, Luo J, Dajun Y.
Potent non-phosphate-containing Grb2 SH2 domain inhibitors.
Peptide Science 1999. Proc 36th Jap Pep Symp: 49-52, 2000. [Journal]
108)  Zhang X, Lee YK, Kelley JA, Burke TR.
Preparation of aryl isothiocyanates via protected phenylthiocarbamates and application to the synthesis of caffeic acid (4-isothiocyanato)phenyl ester.
J Org Chem. 65: 6237-40, 2000. [Journal]
109)  Gao Y, Burke TR.
Stereoselective Preparation of L-4-(2'-Malonyl)phenylalanine suitably protected for Fmoc-based Synthesis of Potent Signal Transduction Inhibitory Ligands.
Synlett. 1: 134-136, 2000. [Journal]
110)  Zhang YL, Yao ZJ, Sarmiento M, Wu L, Burke TR, Zhang ZY.
Thermodynamic study of ligand binding to protein-tyrosine phosphatase 1B and its substrate-trapping mutants.
J Biol Chem. 275: 34205-12, 2000. [Journal]
111)  Burke TR, Liu DG, Gao Y.
Use of a Heck reaction for the synthesis of a new alpha-azido phosphotyrosyl mimetic suitably protected for peptide synthesis.
J Org Chem. 65: 6288-91, 2000. [Journal]
112)  Pluymers W, Neamati N, Pannecouque C, Fikkert V, Marchand C, Burke TR, Pommier Y, Schols D, De Clercq E, Debyser Z, Witvrouw M.
Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters.
Mol Pharmacol. 58: 641-8, 2000. [Journal]
113)  Chen H, Cong LN, Li Y, Yao ZJ, Wu L, Zhang ZY, Burke TR, Quon MJ.
A phosphotyrosyl mimetic peptide reverses impairment of insulin-stimulated translocation of GLUT4 caused by overexpression of PTP1B in rat adipose cells.
Biochemistry. 38: 384-9, 1999. [Journal]
114)  Lin Z, Neamati N, Zhao H, Kiryu Y, Turpin JA, Aberham C, Strebel K, Kohn K, Witvrouw M, Pannecouque C, Debyser Z, De Clercq E, Rice WG, Pommier Y, Burke TR.
Chicoric acid analogues as HIV-1 integrase inhibitors.
J Med Chem. 42: 1401-14, 1999. [Journal]
115)  Burke TR, Luo J, Yao ZJ, Gao Y, Zhao H, Milne GW, Guo R, Voigt JH, King CR, Yang D.
Monocarboxylic-based phosphotyrosyl mimetics in the design of GRB2 SH2 domain inhibitors.
Bioorg Med Chem Lett. 9: 347-52, 1999. [Journal]
116)  Yao ZJ, King CR, Cao T, Kelley J, Milne GW, Voigt JH, Burke TR.
Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands.
J Med Chem. 42: 25-35, 1999. [Journal]
117)  Yao ZJ, Gao Y, Burke Jr TR.
Preparation of (L)-N(alpha)-Fmoc-4-[di(tert-butyl)phosphonomethyl]phenylalanine from L-tyrosine.
Tetrahedron Asymm. 10: 3727-3734, 1999. [Journal]
118)  Sajan MP, Standaert ML, Bandyopadhyay G, Quon MJ, Burke TR, Farese RV.
Protein kinase C-zeta and phosphoinositide-dependent protein kinase-1 are required for insulin-induced activation of ERK in rat adipocytes.
J Biol Chem. 274: 30495-500, 1999. [Journal]
119)  Long YQ, Yao ZJ, Voigt JH, Lung FD, Luo JH, Burke TR, King CR, Yang D, Roller PP.
Structural requirements for Tyr in the consensus sequence Y-E-N of a novel nonphosphorylated inhibitor to the Grb2-SH2 domain.
Biochem Biophys Res Commun. 264: 902-8, 1999. [Journal]
120)  Yao ZJ, Ye B, Zhao H, Yan X, Wu L, Barford D, Wang S, Zhang ZY, Burke Jr TR.
Structure-based design of small molecule protein-tyrosine phosphatase inhibitors.
Peptides: Frontiers of Peptide Science. Tam JP, Kaumaya PTP (eds) ESCOM, Dordect: 183-185, 1999. [Journal]
121)  Yao ZJGAOY, Voigt JH, Ford H, Burke TR.
Synthesis of Fmoc-protected 4-Carboxydifluoromethyl-L-phenylalanine: A Phosphotyrosyl Mimetic of Potential Use for Signal Transduction Studies.
Tetrahedron. 55: 2865-2874, 1999. [Journal]
122)  Otaka A, Miyoshi K, Kaneko M, Burke Jr TR, Roller PP, Tamamura H, Fujii N.
Development of new effecient deprotection methodologies for the synthesis of phosphoamino acids-containing peptides.
Peptides 1996. Ramage & Epton (Eds), Kingswinford, England: 701-702, 1998. [Journal]
123)  Burke TR, Yao ZJ, Zhao H, Milne GWA, Wu L, Zhang ZY, Voigt JH.
Enantioselective Synthesis of Nonphosphorous-containing Phosphotyrosyl Mimetics and their Use in the Preparation of Tyrosine Phosphatase Inhibitory Peptides.
Tetrahedron. 54: 9981-9994, 1998. [Journal]
124)  Zhao H, Burke TR.
Facile Syntheses of (2R,3R)-(-)-and (2S,3S)-(+)-Chicoric Acids.
Syn Comm. 28: 737-740, 1998. [Journal]
125)  Roller PP, Wu L, Zhang ZY, Burke TR.
Potent inhibition of protein-tyrosine phosphatase-1B using the phosphotyrosyl mimetic fluoro-O-malonyl tyrosine (FOMT).
Bioorg Med Chem Lett. 8: 2149-50, 1998. [Journal]
126)  Burke TR, Zhang ZY.
Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery.
Biopolymers. 47: 225-41, 1998. [Journal]
127)  Neamati N, Hong H, Owen JM, Sunder S, Winslow HE, Christensen JL, Zhao H, Burke TR, Milne GW, Pommier Y.
Salicylhydrazine-containing inhibitors of HIV-1 integrase: implication for a selective chelation in the integrase active site.
J Med Chem. 41: 3202-9, 1998. [Journal]
128)  Groves MR, Yao ZJ, Roller PP, Burke TR, Barford D.
Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics.
Biochemistry. 37: 17773-83, 1998. [Journal]
129)  Lubkowski J, Yang F, Alexandratos J, Wlodawer A, Zhao H, Burke TR, Neamati N, Pommier Y, Merkel G, Skalka AM.
Structure of the catalytic domain of avian sarcoma virus integrase with a bound HIV-1 integrase-targeted inhibitor.
Proc Natl Acad Sci U S A. 95: 4831-6, 1998. [Journal]
130)  Yao ZJ, Ye B, Wu XW, Wang S, Wu L, Zhang ZY, Burke TR.
Structure-based design and synthesis of small molecule protein-tyrosine phosphatase 1B inhibitors.
Bioorg Med Chem. 6: 1799-810, 1998. [Journal]
131)  Kouki A, Mitsios JV, Sakarellos-Daitsiotis M, Sakarellos C, Tselepis AD, Tsikaris V, Tsoukatos DC.
Synthesis and conformation of tyrosine phosphatase inhibitory cyclic peptides.
Eur. Peptide Symposium Proceedings. Ramage & Epton (Eds), Kingswinford, England: 199-200, 1998. [Journal]
132)  Zhao H, Neamati N, Mazumder A, Sunder S, Pommier Y, Burke TR.
Arylamide inhibitors of HIV-1 integrase.
J Med Chem. 40: 1186-94, 1997. [Journal]
133)  Giorgetti-Peraldi S, Ottinger E, Wolf G, Ye B, Burke TR, Shoelson SE.
Cellular effects of phosphotyrosine-binding domain inhibitors on insulin receptor signaling and trafficking.
Mol Cell Biol. 17: 1180-8, 1997. [Journal]
134)  Zhao H, Neamati N, Hong H, Mazumder A, Wang S, Sunder S, Milne GW, Pommier Y, Burke TR.
Coumarin-based inhibitors of HIV integrase.
J Med Chem. 40: 242-9, 1997. [Journal]
135)  Zhao H, Neamati N, Pommier Y, Burke Jr TR.
Design and synthesis of photoactivatable coumarin-containing HIV-1 integrase inhibitors.
Heterocycles. 45: 2277-2282, 1997. [Journal]
136)  Neamati N, Mazumder A, Zhao H, Sunder S, Burke TR, Schultz RJ, Pommier Y.
Diarylsulfones, a novel class of human immunodeficiency virus type 1 integrase inhibitors.
Antimicrob Agents Chemother. 41: 385-93, 1997. [Journal]
137)  Hong H, Neamati N, Wang S, Nicklaus MC, Mazumder A, Zhao H, Burke TR, Pommier Y, Milne GW.
Discovery of HIV-1 integrase inhibitors by pharmacophore searching.
J Med Chem. 40: 930-6, 1997. [Journal]
138)  Zhao H, Neamati N, Sunder S, Hong H, Wang S, Milne GW, Pommier Y, Burke TR.
Hydrazide-containing inhibitors of HIV-1 integrase.
J Med Chem. 40: 937-41, 1997. [Journal]
139)  Ullrich KJ, Rumrich G, Burke TR, Shirazi-Beechey SP, Lang H.
Interaction of Alkyl/Arylphosphonates, phosphonocarboxylates and diphosphonates with different anion transport systems in the proximal renal tubule.
J Pharmacol Exp Ther. 283: 1223-9, 1997. [Journal]
140)  Oligino L, Lung FD, Sastry L, Bigelow J, Cao T, Curran M, Burke TR, Wang S, Krag D, Roller PP, King CR.
Nonphosphorylated peptide ligands for the Grb2 Src homology 2 domain.
J Biol Chem. 272: 29046-52, 1997. [Journal]
141)  Zhao H, Burke TR.
Pentafluorophenyl Ester Activation for the Preparation of N, N'-Diaroylhydrazines.
Tetrahedron. 53: 4219-4230, 1997. [Journal]
142)  Burke TR, Yao ZJ, Smyth MS, Ye B.
Phosphotyrosyl-based Motifs in the Structure-Based Design of Protein-Tyrosine Kinase-Dependent Signal Transduction Inhibitors.
Curr Pharm Design. 3: 291-304, 1997. [Journal]
143)  Akamatsu M, Roller PP, Chen L, Zhang ZY, Ye B, Burke TR.
Potent inhibition of protein-tyrosine phosphatase by phosphotyrosine-mimic containing cyclic peptides.
Bioorg Med Chem. 5: 157-63, 1997. [Journal]
144)  Ye B, Yao ZJ, Burke TR.
Synthesis of a New Tyrosine Analogue Having (Chi 1) and (Chi 2) Angles Constrained to Values Observed for an SH2 Domain-bound Phosphotyrosyl Residue.
J Org Chem. 62: 5428-5431, 1997. [Journal]
145)  Burke TR, Ye B, Akamatsu M, Ford H, Yan X, Kole HK, Wolf G, Shoelson SE, Roller PP.
4'-O-[2-(2-fluoromalonyl)]-L-tyrosine: a phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides.
J Med Chem. 39: 1021-7, 1996. [Journal]
146)  Mazumder A, Wang S, Neamati N, Nicklaus M, Sunder S, Chen J, Milne GW, Rice WG, Burke TR, Pommier Y.
Antiretroviral agents as inhibitors of both human immunodeficiency virus type 1 integrase and protease.
J Med Chem. 39: 2472-81, 1996. [Journal]
147)  Natarajan K, Singh S, Burke TR, Grunberger D, Aggarwal BB.
Caffeic acid phenethyl ester is a potent and specific inhibitor of activation of nuclear transcription factor NF-kappa B.
Proc Natl Acad Sci U S A. 93: 9090-5, 1996. [Journal]
148)  Stanwell C, Ye B, Yuspa SH, Burke TR.
Cell protein cross-linking by erbstatin and related compounds.
Biochem Pharmacol. 52: 475-80, 1996. [Journal]
149)  Barchi JJ, Nomizu M, Otaka A, Roller PP, Burke TR.
Conformational analysis of cyclic hexapeptides designed as constrained ligands for the SH2 domain of the p85 subunit of phosphatidylinositol-3-OH kinase.
Biopolymers. 38: 191-208, 1996. [Journal]
150)  Smyth MS, Burke TR.
Enantioselective Synthesis of N-Boc and N-Fmoc Protected Dethyl 4-Phosphono(difluoroniethyl)-1-phenylalanine (F(2)Pmp).
Org Prep Proc Intl. 28: 77-81, 1996. [Journal]
151)  Ye B, Otaka A, Burke TR.
Preparation of N-alpha-Boc 4-O-Diethylphospho-L-azatyrosine, a Reagent Potentially Useful for the Synthesis of Signal Transduction Related Peptides.
Synlett. 459-, 1996. [Journal]
152)  Burke TR, Ye B, Yan X, Wang S, Jia Z, Chen L, Zhang ZY, Barford D.
Small molecule interactions with protein-tyrosine phosphatase PTP1B and their use in inhibitor design.
Biochemistry. 35: 15989-96, 1996. [Journal]
153)  Ye B, Burke TR.
Synthesis of a Difluorophosphonomethyl-containing Phosphatase Inhibitor Designed from the X-ray Structure of a PTP1B-bound Ligand.
Tetrahedron. 52: 9963-9970, 1996. [Journal]
154)  Ye B, Burke TR.
A Concise Synthesis of the Differentiating Antibiotic L-Azatyrosine.
J Org Chem. 60: 2640-2641, 1995. [Journal]
155)  Akamatsu M, Ye B, Yan XJ, Kole HK, Burke Jr TR, Roller PP.
Characterization of tyrosine-phosphate mimick containing tyrosine phosphatase inhibitory peptides.
Japan Peptide Symposium Proceedings. 369-372, 1995. [Journal]
156)  Burke TR, Barchi JJ, George C, Wolf G, Shoelson SE, Yan X.
Conformationally constrained phosphotyrosyl mimetics designed as monomeric Src homology 2 domain inhibitors.
J Med Chem. 38: 1386-96, 1995. [Journal]
157)  Otaka A, Miyoshi K, Tamamura H, Roller PP, Burke Jr TR, Fuji N.
Development of a practical synthetic methodology using dimethylphosphono amino acid for phosphopeptides.
Peptides: Chemistry Structure and Biology. Kaumaya PTP & Hodges RS (eds), ESCOM, Leiden: 442-443, 1995. [Journal]
158)  Otaka A, Miyoshi K, Kaneko M, Tamamura H, Fuji N, Nomizu M, Burke TR, Roller PP.
Development of Efficient 2-Step Deprotection Methodology for Dimehtyl-protected Phosphoamino Acid-containing Peptide Resins and its Application to the Practical Synthesis of Phosphopeptides.
J Org Chem. 60: 3967-3974, 1995. [Journal]
159)  Wange RL, Isakov N, Burke TR, Otaka A, Roller PP, Watts JD, Aebersold R, Samelson LE.
F2(Pmp)2-TAM zeta 3, a novel competitive inhibitor of the binding of ZAP-70 to the T cell antigen receptor, blocks early T cell signaling.
J Biol Chem. 270: 944-8, 1995. [Journal]
160)  Burke TR, Fesen MR, Mazumder A, Wang J, Carothers AM, Grunberger D, Driscoll J, Kohn K, Pommier Y.
Hydroxylated aromatic inhibitors of HIV-1 integrase.
J Med Chem. 38: 4171-8, 1995. [Journal]
161)  Ye B, Burke TR.
L-O-(2-Malonyl)tyrosine (L-OMT) A New Phosphotyrosyl Mimic Suitably Protected for Solid-phase Synthesis of Signal Transduction Inhibitory Peptides.
Tet Lett. 36: 4733-4736, 1995. [Journal]
162)  Ye B, Akamatsu M, Shoelson SE, Wolf G, Giorgetti-Peraldi S, Yan X, Roller PP, Burke TR.
L-O-(2-malonyl)tyrosine: a new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides.
J Med Chem. 38: 4270-5, 1995. [Journal]
163)  Kole HK, Smyth MS, Russ PL, Burke TR.
Phosphonate inhibitors of protein-tyrosine and serine/threonine phosphatases.
Biochem J. 311 ( Pt 3): 1025-31, 1995. [Journal]
164)  Otaka A, Miyoshi K, Roller PP, Burke TR, Tamamura H, Fuji N.
Practical Synthesis of Phosphopeptides Using Dimethyl-Protected Phosphoamino Acid Derivatives.
J Chem Soc Chem Comm. 387-389, 1995. [Journal]
165)  Kole HK, Akamatsu M, Ye B, Yan X, Barford D, Roller PP, Burke TR.
Protein-tyrosine phosphatase inhibition by a peptide containing the phosphotyrosyl mimetic, L-O-malonyltyrosine.
Biochem Biophys Res Commun. 209: 817-22, 1995. [Journal]
166)  Otaka A, Miyoshi K, Burke TR, Roller PP, Kubota H, Tamamura H, Fuji N.
Synthesis and Application of N-Boc-L-2-amino-4-(diethylphosphono)-4,4-Difluorobutanoic Acid for Solid Phase Synthesis of Nonhydrolyzable Phosphoserine Peptide Analogs.
Tet Lett. 36: 927-930, 1995. [Journal]
167)  Stanwell C, Burke TR, Yuspa SH.
The erbstatin analogue methyl 2,5-dihydroxycinnamate cross-links proteins and is cytotoxic to normal and neoplastic epithelial cells by a mechanism independent of tyrosine kinase inhibition.
Cancer Res. 55: 4950-6, 1995. [Journal]
168)  Chen L, Wu L, Otaka A, Smyth MS, Roller PP, Burke TR, den Hertog J, Zhang ZY.
Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein-tyrosine phosphatases?.
Biochem Biophys Res Commun. 216: 976-84, 1995. [Journal]
169)  Burke TR, Nomizu M, Otaka A, Smyth MS, Roller PP, Case RD, Wolf G, Shoelson SE.
Cyclic peptide inhibitors of phosphatidylinositol 3-kinase p85 SH2 domain binding.
Biochem Biophys Res Commun. 201: 1148-53, 1994. [Journal]
170)  Smyth MS, Burke TR.
Enantioselective Synthesis of N-Boc and N-Fmoc Protected Dethyl 4-Phosphono(difluoroniethyl)-L-phenylalanine - Agents Suitable for the Solid-Phase Synthesis or Peptides Containing Nonhydrolyzable Analogs of O-Phosphotyrosine.
Tet Lett. 35: 551-554, 1994. [Journal]
171)  Burke TR, Smyth MS, Otaka A, Nomizu M, Roller PP, Wolf G, Case R, Shoelson SE.
Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors.
Biochemistry. 33: 6490-4, 1994. [Journal]
172)  Roller PP, Otaka A, Nomizu M, Smyth MS, Barchi JJ, Burke TR, Case RD, Wolf G, Shoelson SE.
Norleucine as a Replacement for Methionine in Phosphatase-Resistant Linear and Cyclic-Peptides which Bind to P85 SH2 Domains.
Bioorg & Med Chem Lett. 4: 1879-1882, 1994. [Journal]
173)  Burke TR, Kole HK, Roller PP.
Potent inhibition of insulin receptor dephosphorylation by a hexamer peptide containing the phosphotyrosyl mimetic F2Pmp.
Biochem Biophys Res Commun. 204: 129-34, 1994. [Journal]
174)  Burke TR.
Protein-tyrosine kinases: potential targets for anticancer drug development.
Stem Cells. 12: 1-6, 1994. [Journal]
175)  Roller PP, Toaka A, Nomizu M, Yan X, Smyth MS, Barchi Jr JJ, Shoelson SE, Burke Jr TR.
Synthesis and structure activity studies of phosphatase-resistant SH2 domain inhibiting peptides.
Peptides 1994. HLS Maia (Ed) ESCOM, Leiden, The Netherlands: 355-356, 1994. [Journal]
176)  Nomizu M, Otaka A, Smyth MS, Shoelson SE, Case RD, Burke Jr TR, Roller PP.
Synthesis and structure of SH2 binding peptides containing phosphonomethyl-phenylalanine and analogs.
Peptide Chemistry 1993. Okada Y (Ed), Osaka, Japan: 281-284, 1994. [Journal]
177)  Otaka A, Nomizu M, Smyth MS, Shoelson SE, Case RD, Burke Jr TR, Roller PP.
Synthesis and structure-activity studies of SH2 binding peptides containing hydrolytically stable analogs of 0-phosphotyrosine.
Peptides: Chemistry and Biology. Hodges, R.S. (ed.). ESCOM Sci. Publishers, Leiden: 631-633, 1994. [Journal]
178)  Ye B, Akamatsu M, Shoelson SE, Wolf G, Giorgetti-Peraldi S, Yan X, Roller PP, Burke TR.
Synthesis of Phosphonomethyl-phenylalanine and Protein Tyrosine Kinase/SH2 Interactions.
Tetrahedron. 50: 2691-2702, 1994. [Journal]
179)  Xiao S, Rose DW, Sasaoka T, Maegawa H, Burke TR, Roller PP, Shoelson SE, Olefsky JM.
Syp (SH-PTP2) is a positive mediator of growth factor-stimulated mitogenic signal transduction.
J Biol Chem. 269: 21244-8, 1994. [Journal]
180)  Burke TR, Lim B, Marquez VE, Li ZH, Bolen JB, Stefanova I, Horak ID.
Bicyclic compounds as ring-constrained inhibitors of protein-tyrosine kinase p56lck.
J Med Chem. 36: 425-32, 1993. [Journal]
181)  Otaka A, Burke Jr TR, Smyth MS, Nomizu M, Roller PP.
Deprotection and Cleavage Methods for Protected Peptide Resins Containing 4-[(Diethylphosphono)difluoromethyl]-D,L-phenylalanine Residues.
Tet Lett. 34: 7039-7042, 1993. [Journal]
182)  Smyth MS, Stefanova I, Horak ID, Burke TR.
Hydroxylated 2-(5'-salicyl)naphthalenes as protein-tyrosine kinase inhibitors.
J Med Chem. 36: 3015-20, 1993. [Journal]
183)  Smyth MS, Stefanova I, Hartmann F, Horak ID, Osherov N, Levitzki A, Burke TR.
Non-amine based analogues of lavendustin A as protein-tyrosine kinase inhibitors.
J Med Chem. 36: 3010-4, 1993. [Journal]
184)  Burke TR, Smyth MS, Nomizu M, Otaka A, Roller PP.
Preparation of Fluoro-4-(phosphonomethyl)-D,L-phenylalanine and Hydroxy-4-(Phosphonomethyl(-D,L-Phenylalanine Suitably Protected for Solid Phase Synthesis of Peptides Containing Hydrolytically Stable Analogs of O-Phosphotyrosine.
J Org Chem. 58: 1336-1340, 1993. [Journal]
185)  Knight M, Takahashi K, Burke Jr TR, Pineda JD, Fishbeyn VA, Jensen RT, Moody TW.
Synthesis and Biological Activity of Cholecystokinin Antagonists.
Growth Factors, Peptides and Receptors. Ed. T.W. Moody, Plenum Press, New York: 211-223, 1993. [Journal]
186)  Burke TR, Smyth MS, Otaka A, Roller PP.
Synthesis of 4-Phosphono(difluoromethyl)-D,L-Phenylalanine and N-Boc and N-Fmoc Derivatives Suitably Protected for Solid Phase Synthesis of Nonhydrozylable Phosphotyrosyl Peptide Analogs.
Tet Lett. 34: 4125-4128, 1993. [Journal]
187)  Smyth MS, Ford H, Burke TR.
A General Method for the Preparation of Benzylic alpha, alpha-Difluorophosphonic Acids - Nonhydrolyzable Mimetics of Phosphotyrosine.
Tet Lett. 33: 4137-4140, 1992. [Journal]
188)  Burke TR, Russ PL, Marquez VE.
A New Synthetic Method for the Synthesis of Hydroxylated Isoquinolines - Preparation of Methyl 6,7-Dihydroxy-isoquinoline-3-carboxylate and 7,8-Dihydroxy-isoquinoline-3-carboxylate, Potential Protein Tyrosine Kinase Inhibitors.
Heterocycles. 34: 757-764, 1992. [Journal]
189)  Burke TR, Ford H, Osherov N, Levitzki A, Stefanova I, Horak ID, Marquez VE.
Arylamides of Hydroxylated Isoquinolines as Protien Tyrosine Kinase Inhibitors.
Bioorg & Med Chem Lett. 2: 1771-1774, 1992. [Journal]
190)  Domchek SM, Auger KR, Chatterjee S, Burke TR, Shoelson SE.
Inhibition of SH2 domain/phosphoprotein association by a nonhydrolyzable phosphonopeptide.
Biochemistry. 31: 9865-70, 1992. [Journal]
191)  Burke Jr TR.
Protein-tyrosine kinase inhibitors.
Drug Future. 17: 119-131, 1992. [Journal]
192)  Nicklaus MC, Milne GW, Burke TR.
QSAR of conformationally flexible molecules: comparative molecular field analysis of protein-tyrosine kinase inhibitors.
J Comput Aided Mol Des. 6: 487-504, 1992. [Journal]
193)  Burke TR.
A Direct Approach Toward the Synthesis of Analogs of Erbstatin.
Org Prep Proc Intl. 23: 127-130, 1991. [Journal]
194)  Li ZH, Burke TR, Bolen JB.
Analysis of styryl-based inhibitors of the lymphocyte tyrosine protein kinase p56lck.
Biochem Biophys Res Commun. 180: 1048-56, 1991. [Journal]
195)  Burke TR, Li ZH, Bolen JB, Chapekar M, Gang Y, Glazer RI, Rice KC, Marquez VE.
Examination of the possible mediation of antineoplastic effects of opiates through the inhibition of tyrosine-specific protein kinases.
Biochem Pharmacol. 41: R17-20, 1991. [Journal]
196)  Linders JT, Burke TR, Jacobson AE, Rice KC.
Oxide-bridged 5-phenylmorphans as probes for narcotic receptor mediated phenomena.
NIDA Res Monogr. 105: 388-9, 1991. [Journal]
197)  Burke TR, Li ZH, Bolen JB, Marquez VE.
Phosphonate-containing inhibitors of tyrosine-specific protein kinases.
J Med Chem. 34: 1577-81, 1991. [Journal]
198)  Burke TR, Russ P, Lim B.
Preparation of 4-[bis(tert-Butoxy)phosphorylmethyl]-N-(fluoren-9-ylmethyoxycarbonyl)-DL-phenylalanine - A Hydrolytically Stable Analog of O-Phosphotyrosine Potentially Suitable for Peptide Synthesis.
Synthesis-Stuttgart. 1019-1020, 1991. [Journal]
199)  Shoelson SE, Chatterjee S, Chaudhuri M, Burke TR.
Solid Phase Synthesis of Nonhydrolyzable Phosphotyrosyl Peptide Analogs with N-alpha-Fmoc-(O,O-di-tert-buytl)phosphono-para-methylphenylalanine.
Tet Lett. 32: 6061-6064, 1991. [Journal]
200)  Burke TR, Li ZH, Bolen JB, Marquez VE.
Structural Influences of Styryl-based Inhibitors on Epidermal Growth Factor Receptor and P56LCK Tyrosine Specific Protein Kinases.
Bioorg & Med Chem Lett. 1: 165-168, 1991. [Journal]
201)  Burke Jr TR, Chandrasekhar B, Gottlieb M.
Analogs of the cyclic depsipeptide antibiotic viscosin.
Peptides, Structure and Function. Proceedings of the 11th American Peptide Symposium: 132-133, 1990. [Journal]
202)  Knight M, Moody TW, Pineda DD, Cohen SN, Burke Jr TR.
Design of a cyclic bombesin analogue.
Peptides, Structure and Function. Proceedings of the 11th American Peptide Symposium: 285-287, 1990. [Journal]
203)  Creveling CR, Bell ME, Burke TR, Chang E, Lewandowski-Lovenberg GA, Kim CH, Rice KC, Daly JW.
Procaine isothiocyanate: an irreversible inhibitor of the specific binding of [3H]batrachotoxinin-A benzoate to sodium channels.
Neurochem Res. 15: 441-8, 1990. [Journal]
204)  Newman AH, Channing MA, Finn RD, Dunn B, Simpson N, Carson RE, Ostrowski NL, Cohen RM, Burke JR TR, Larson SM, Rice KC.
Ligands for imaging opiod receptors in conscious humans by positron emission tomography (PET).
NIDA Res Mon. US Govt Printing Office, Washington, DC 20402: 117-121, 1989. [Journal]
205)  Burke TR, Chandrasekhar B.
Preparative reversed-phase high-performance liquid chromatography in the synthesis of viscosin, a cyclic depsipeptide.
J Chromatogr. 484: 293-8, 1989. [Journal]
206)  Burke Jr TR, Knight M, Chandrasekhar B, Ferretti J.
Solid phase synthesis of viscosin, a cyclic depsipeptide with antibacterial and antiviral properties.
Tet Lett. 30: 519-522, 1989. [Journal]
207)  Knight M, Mack GD, Perkins R, Burke TR.
Reversed-phase preparative chromatography of [D-Ala1]-peptide T amide.
J Chromatogr. 444: 345-8, 1988. [Journal]
208)  de Costa BR, George C, Burke TR, Rafferty MF, Contreras PC, Mick SJ, Jacobson AE, Rice KC.
Synthesis, configuration, and evaluation of two conformationally restrained analogues of phencyclidine.
J Med Chem. 31: 1571-5, 1988. [Journal]
209)  Jacobson AE, Rice KC, Burke TR, Lupinacci L, Mattson MV, Aceto MD, Harris LS.
2,5-Dimethyl-2'-hydroxy-9 alpha- and 9 beta-(3-methylbutyl)-6,7-benzomorphans and N-substituted compounds in the 9 alpha-(3-methylbutyl) series: chemistry, pharmacology, and biochemistry.
J Pharm Sci. 76: 248-52, 1987. [Journal]
210)  Burke TR, Knight M.
Counter-current chromatographic purification of [D-Ala]peptide T amide.
J Chromatogr. 411: 431-5, 1987. [Journal]
211)  Newton DL, Burke TR, Rice KC, Klee CB.
Synthesis and properties of CAPP1-calmodulin.
Methods Enzymol. 139: 405-17, 1987. [Journal]
212)  Ostrowski NL, Burke TR, Rice KC, Pert A, Pert CB.
The pattern of [3H]cyclofoxy retention in rat brain after in vivo injection corresponds to the in vitro opiate receptor distribution.
Brain Res. 402: 275-86, 1987. [Journal]
213)  Rothman RB, Danks JA, Jacobson AE, Burke TR, Rice KC, Tortella FC, Holaday JW.
Morphine tolerance increases mu-noncompetitive delta binding sites.
Eur J Pharmacol. 124: 113-9, 1986. [Journal]
214)  Burke TR, Jacobson AE, Rice KC, Silverton JV, Simonds WF, Streaty RA, Klee WA.
Probes for narcotic receptor mediated phenomena. 12. cis-(+)-3-Methylfentanyl isothiocyanate, a potent site-directed acylating agent for delta opioid receptors. Synthesis, absolute configuration, and receptor enantioselectivity.
J Med Chem. 29: 1087-93, 1986. [Journal]
215)  Burke TR, Jacobson AE, Rice KC, Weissman BA, Huang HC, Silverton JV.
Probes for narcotic receptor mediated phenomena. 9. Synthesis of (+/-)-(3 alpha,6a alpha,11a beta)-1,3,4,5,6,11a-hexahydro-2-methyl-2H-3,6a- methanobenzofuro[2,3-c]azocin-10-ol, an oxide-bridged 5-(m-hydroxyphenyl)morphan.
J Med Chem. 29: 748-51, 1986. [Journal]
216)  Rothman RB, Danks JA, Herkenham M, Jacobson AE, Burke TR, Rice KC.
Evidence that the delta-selective alkylating agent, fit, alters the mu-noncompetitive opiate delta binding site.
Neuropeptides. 6: 227-37, 1985. [Journal]
217)  Larson SM, Channing MA, Rice KR, Pert CB, Eckelman WC, Burke TR, Bennett JM, Carson RE, Dichiro G.
Imaging Opiate Receptors by Positron Tomography (PET) - Evaluation by Displacement of 3-Acetyl-6-deoxy-6-beta-F-18-fluoronal Trexone with Active and Inactive Naloxone.
J Nucl Med. 26: P53-P53, 1985. [Journal]
218)  Lutz RA, Costa T, Cruciani RA, Jacobson AE, Rice KC, Burke TR, Krumins SA, Rodbard D.
Increased affinity of dimeric enkephalins is not dependent on receptor density.
Neuropeptides. 6: 167-74, 1985. [Journal]
219)  Rothman RB, Danks JA, Jacobson AE, Burke TR, Rice KC.
Leucine enkephalin noncompetitively inhibits the binding of [3H]naloxone to the opiate mu-recognition site: evidence for delta----mu binding site interactions in vitro.
Neuropeptides. 6: 351-63, 1985. [Journal]
220)  Rothman RB, Bykov V, Danks JA, Jacobson AE, Burke TR, Rice KC, Herkenham M.
Preparation of rat brain membranes highly enriched with opiate kappa binding sites using site-directed acylating agents: optimization of assay conditions.
Neuropeptides. 6: 503-16, 1985. [Journal]
221)  Burke TR, Rice KC, Pert CB.
Probes for Narcotic Receptor Mediated Phenomena. 11. Synthesis of 17-Methyl and 17-Cyclopropylmethyl-3,14-dihydroxy-4,5-alpha-epoxy-6-beta-fluoromorphinans (Foxy and Cyclofoxy) as Models of Opioid Ligands Suitable for Positron Emission Transaxial Tomography.
Heterocycles. 23: 99-106, 1985. [Journal]
222)  Simonds WF, Burke TR, Rice KC, Jacobson AE, Klee WA.
Purification of the opiate receptor of NG108-15 neuroblastoma-glioma hybrid cells.
Proc Natl Acad Sci U S A. 82: 4974-8, 1985. [Journal]
223)  Channing MA, Eckelman WC, Bennett JM, Burke TR, Rice KC.
Radiosynthesis of [18F]3-acetylcyclofoxy: a high affinity opiate antagonist.
Int J Appl Radiat Isot. 36: 429-33, 1985. [Journal]
224)  Channing MA, Eckelman WC, Bennett JM, Burke TR, Rice KC, Larson SM.
Radiosynthesis of F-18-3-Acetoylcyclofoxy - A High-Affinity Opiate Anatagonist.
J Nucl Med. 26: P37-P38, 1985. [Journal]
225)  Pert CB, Danks JA, Channing MA, Eckelman WC, Larson SM, Bennett JM, Burke TR, Rice KC.
3-[18F]Acetylcyclofoxy: a useful probe for the visualization of opiate receptors in living animals.
FEBS Lett. 177: 281-6, 1984. [Journal]
226)  Weissman BA, Burke TR, Rice KC, Skolnick P.
Alkyl-substituted gamma-butyrolactones inhibit [35S]TBPS binding to a GABA linked chloride ionophore.
Eur J Pharmacol. 105: 195-6, 1984. [Journal]
227)  Rothman RB, Danks JA, Pert CB, Jacobson AE, Burke TR, Rice KC.
Ionic conditions differentially affect 3H-DADL binding to type-I and type-II opiate delta receptors in vitro.
Neuropeptides. 4: 261-8, 1984. [Journal]
228)  Rothman RB, Pert CB, Jacobson AE, Burke TR, Rice KC.
Morphine noncompetitively inhibits [3H]leucine enkephalin binding to membranes lacking type-II delta binding sites: evidence for a two-site allosteric model.
Neuropeptides. 4: 257-60, 1984. [Journal]
229)  Koek W, Woods JH, Rice KC, Jacobson AE, Huguenin PN, Burke TR.
Phencyclidine-induced catalepsy in pigeons: specificity and stereoselectivity.
Eur J Pharmacol. 106: 635-8, 1984. [Journal]
230)  Rothman RB, Bowen WD, Bykov V, Schumacher UK, Pert CB, Jacobson AE, Burke TR, Rice KC.
Preparation of rat brain membranes greatly enriched with either type-I-delta or type-II-delta opiate binding sites using site directed alkylating agents: evidence for a two-site allosteric model.
Neuropeptides. 4: 201-15, 1984. [Journal]
231)  Burke TR, Jacobson AE, Rice KC, Weissman BA, Silverton JV.
Probes for narcotic receptor mediated phenomena 3. Oxide bridged 5-phenylmorphans.
NIDA Res Monogr. 49: 109-13, 1984. [Journal]
232)  Burke TR, Jacobson AE, Rice KC.
Probes for Narcotic Receptor Mediated Phenomena. 4. Synthesis of (+/-)2,3,4,5,6,6A-Hexahydro-3-methyl-8-hyroxy-1H-4,11B-methanobenzofuro[3,2-D]azocine, an Oxide-Bridged 5-(meta-hydroxyphenyl)morphan.
J Org Chem. 49: 1051-1056, 1984. [Journal]
233)  Burke TR, Jacobson AE, Rice KC, Silverton JV.
Probes for Narcotic Receptor Mediated Phenomena. 6. Synthesis (+/-)-(1-alpha, 4A-alpha, 9A-beta)-1,3,4-9A-Tetrahydrox-2-methyl-2H-1,4A-propanobezofuro[2,3-C]pyridin-8-ol, an Oxide-Bridged 5-(3-Hydroxyphenyl)morphan.
J Org Chem. 49: 2508-2510, 1984. [Journal]
234)  Burke TR, Bajwa BS, Jacobson AE, Rice KC, Streaty RA, Klee WA.
Probes for narcotic receptor mediated phenomena. 7. Synthesis and pharmacological properties of irreversible ligands specific for mu or delta opiate receptors.
J Med Chem. 27: 1570-4, 1984. [Journal]
235)  Burke TR, Rice KC, Jacobson AE, Simonds WF, Klee WA.
Probes for Narcotic Receptor Mediated Phenomena. 8. Tritiation of Irreversible mu-Specific or delta-Specific Opiod receptor Affinity Ligands to High Specific Activity.
J Label Compound Radiopharm. 21: 693-702, 1984. [Journal]
236)  Rothman RB, Danks JA, Jacobson AE, Burke TR, Rice KC, Pert CB.
Tritiated-6-beta-fluoro-6-desoxy-oxymorphone: a highly selective ligand for the opiate mu receptor whose binding is characterized by low nonspecific binding.
Neuropeptides. 4: 311-7, 1984. [Journal]
237)  Newton DL, Burke TR, Rice KC, Klee CB.
Calcium ion dependent covalent modification of calmodulin with norchlorpromazine isothiocyanate.
Biochemistry. 22: 5472-6, 1983. [Journal]
238)  Bayorh MA, Lozovsky D, Rice KC, Burke TR, Kopin IJ.
Cardiovascular and plasma prolactin responses to stereoisomers of phencyclidine.
Pharmacol Biochem Behav. 19: 365-7, 1983. [Journal]
239)  Lozovsky D, Saller CF, Bayorh MA, Chiueh CC, Rice KC, Burke TR, Kopin IJ.
Effects of phencyclidine on rat prolactin, dopamine receptor and locomotor activity.
Life Sci. 32: 2725-31, 1983. [Journal]
240)  Rice KC, Jacobson AE, Burke TR, Bajwa BS, Streaty RA, Klee WA.
Irreversible ligands with high selectivity toward delta and mu opiate receptors.
Science. 220: 314-6, 1983. [Journal]
241)  Morris PL, Burke TR, Phol LR.
Reductive dechlorination of chloramphenicol by rat liver microsomes.
Drug Metab Dispos. 11: 126-30, 1983. [Journal]
242)  Rice KC, Konicki PE, Quirion R, Burke TR, Pert CB.
Synthesis and pharmacological characterization of (+/-)-5,9 alpha-dimethyl-2-[2-(4-fluorophenyl)ethyl]-2'-hydroxy-6,7-benzomorphan (fluorophen), a ligand suitable for visualization of opiate receptors in vivo.
J Med Chem. 26: 1643-5, 1983. [Journal]
243)  Morris PL, Burke TR, George JW, Pohl LR.
A new pathway for the oxidative metabolism of chloramphenicol by rat liver microsomes.
Drug Metab Dispos. 10: 439-45, 1982. [Journal]
244)  Gross BJ, Branchflower RV, Burke TR, Lees DE, Pohl LR.
Bone marrow toxicity in vitro of chloramphenicol and its metabolites.
Toxicol Appl Pharmacol. 64: 557-65, 1982. [Journal]
245)  Klee WA, Simonds WF, Sweat FW, Burke TR, Jacobson AE, Rice KC.
Identification of a Mr 58 000 glycoprotein subunit of the opiate receptor.
FEBS Lett. 150: 125-8, 1982. [Journal]
246)  Burke TR, Branchflower RV, Lees DE, Pohl LR.
Mechanism of defluorination of enflurane. Identification of an organic metabolite in rat and man.
Drug Metab Dispos. 9: 19-24, 1981. [Journal]
247)  Burke Jr TR, Pohl LR.
Synthesis of Deuterated and Tritiated Derivates of Enflurane.
J. Label Compounds Radiopharm. 18: 663-670, 1981. [Journal]
248)  Burke TR, Howald WN, Nelson WL.
Aromatic hydroxylation of oxprenolol. Quantitation and stereoselectivity in the formation of 4'- and 5-hydroxyoxprenolol in vivo in the rat.
Res Commun Chem Pathol Pharmacol. 28: 399-412, 1980. [Journal]
249)  Highet RJ, Burke TR, Trager WF, Pohl LR, Menard RH, Taburet AM, Gillette JR.
Carbon-13 nuclear magnetic resonance studies of spironolactone and several related steroids.
Steroids. 35: 119-32, 1980. [Journal]
250)  Burke TR, Martin JL, George JW, Pohl LR.
Investigation of the mechanism of defluorination of enflurane in rat liver microsomes with specifically deuterated derivatives.
Biochem Pharmacol. 29: 1623-6, 1980. [Journal]
251)  Burke TR, Nelson WL, Mangion M, Hite GJ, Mokler CM, Ruenitz PC.
Resolution, absolute configuration, and antiarrhythmic properties of the enantiomers of disopyramide, 4-(diisopropylamino)-2-(2-pyridyl)-2-phenylbutyramide.
J Med Chem. 23: 1044-8, 1980. [Journal]
252)  Giacomini KM, Giacomini JC, Swezey SE, Harrison DC, Nelson WL, Burke TR, Blaschke TF.
The stereoselective disposition of disopyramide in the dog.
J Cardiovasc Pharmacol. 2: 825-32, 1980. [Journal]
253)  Nelson WL, Burke TR.
Aromatic hydroxylation of beta-adrenergic antagonists. Formation of 4'- and 5'-hydroxy-1-(isopropylamino)-3-[2'-allyloxy)phenoxy]-2-propanol from oxprenolol.
J Med Chem. 22: 1082-8, 1979. [Journal]
254)  Nelson WL, Burke TR.
Metabolism of beta-adrenergic antagonists. Evidence for an arene oxide-NIH shift pathway in the aromatic hydroxylation of oxprenolol.
J Med Chem. 22: 1088-92, 1979. [Journal]
255)  Burke TR, Nelson WL, Buckner CK.
Synthesis of 4'- and 5'-hydroxyoxprenolol:pharmacologically active ring-hydroxylated metabolites of oxprenolol.
J Med Chem. 22: 1535-7, 1979. [Journal]
256)  Nelson WL, Burke Jr TR.
Absolute Configuration of Glycerol Derivatives 5. Oxprenolol Enantiomers.
J. Org. Chem. 43: 3641-3645, 1978. [Journal]
257)  Nelson WL, Burke TR.
Aromatic hydroxylation of beta-adrenergic antagonists. 4- and 5-hydroxylation of 1-(isopropylamino)-3-[2-(allyloxy)phenoxy]-2-propanol (oxprenolol).
J Med Chem. 21: 1185-6, 1978. [Journal]
258)  Nelson WL, Burke TR.
Pathways of propranolol metabolism. Use of the stable isotope twin-ion GC-MS technique to examine the conversion of propranolol to propranolol-diol by 9000g rat liver supernatant.
Res Commun Chem Pathol Pharmacol. 21: 77-85, 1978. [Journal]
259)  Burke T, Oishi S, Shi Z, inventor; DHHS, assignee.
A New Approach Toward Macrocyclization Of Peptides.
Patent Pending, Filed in 2004. Application No. 11/575,723. Pending [Patent]
260)  Bottaro D, Peach M, Nicklaus M, Burke T, Gagani A, Choyke S, Biubellino A, Tan N, inventor; DHHS, assignee.
Compositions and methods for inhibition of hepatocyte growth factor receptor c-Met signaling.
Patent Pending, Filed in 2008. Application No. 61/041,523. Pending [Patent]
261)  Bottaro D, Atabey N, Breckenridge D, Burke T, Giubellino A, Soriano J, inventor; DHHS, assignee.
Inhibition Of Cell Motility And Angiogenesis.
Patent Pending, Filed in 1999. Application No. 11/525,672. Pending [Patent]
262)  Burke T, Gao Y, Yao Z, Yang D, inventor; DHHS, assignee.
Phenylalanine derivatives.
Patent Pending, Filed in 2007. Application No. 11/749,4999. Pending [Patent]
263)  Burke T, Zhao X, Semenova E, Pommier Y, inventor; DHHS, assignee.
Phthalimides and phthalhydrazides as inhibitors of HIV-1 integrase.
Patent Pending, Filed in 2007. Application No. 60/956,636. Pending [Patent]
264)  Rader C, Hofer T, Burke T, Thomas J, inventor; DHHS, assignee.
Selenocysteine mediated hybrid antibody molecules.
Patent Pending, Filed in 2007. Application No. 60/909,665. Pending [Patent]
265)  Burke T, Gao Y, Shi Z, Wei C, inventor; DHHS, assignee.
Sh2 Domain Binding Inhibitors.
Patent Pending, Filed in 2000. Application No. 10/517,717. Pending [Patent]
266)  Burke T, Kang S, Shi Z, inventor; DHHS, assignee.
Sh2 Domain Binding Inhibitors.
Patent Pending, Filed in 2003. Application No. 11/932,424. Pending [Patent]
267)  Bottaro DP, Atabey SN, Breckenridge DE, Burke, Jr. TR, Gao Y, Yao ZJ, inventor; DHHS, assignee.
Inhibition Of Cell Motility And Angiogenesis By Inhibitors Of The Grb2 Sh2-domain.
US Patent: 7,132,392. 2006. [Patent]
268)  Burke T, Gao Y, Yang D, Yao Z, inventor; DHHS, assignee.
Phenylalanine Derivatives.
US Patent: 7,226,991. 2007. [Patent]
269)  Burke T, Wei C, Shi Z, Gao Y, inventor; DHHS, assignee.
SH2 domain binding inhibitors.
US Patent: 7,425,537. 2008. E-Number: E-262-2000/1-US-03. [Patent]
270)  Burke T, Gao Y, Voigt J, Wei C, inventor; DHHS, assignee.
SH2 domain binding inhibitors.
US Patent: 6,977,241. 2005. [Patent]

This page was last updated on 12/22/2008.